# Sagimet Biosciences Inc. Series A (SGMT) fundamentals

Data as of 2026-11-05. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $9.99, market value $708 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Sagimet Biosciences Inc. Series A reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 354.2×**. Each dollar of revenue is priced at 354.2×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.4×**. The shares trade at 2.4× book value; book value is a meaningful part of the valuation.

## Profitability
- **Return on equity: -45.8%**. Return on equity is negative because earnings are negative.
- **Return on assets: -23.9%**. Each dollar of assets produces -23.9% of profit.

## Growth
- **EPS growth (1 yr): -9.0%**. Earnings per share fell 9.0%.

## Financial health
- **Current ratio: 22.82** (quick 22.82). Current assets cover the next year's liabilities 22.82 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Sagimet Biosciences Inc. Series A does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (11 analysts). 11 analysts cover Sagimet Biosciences Inc. Series A; the consensus is strong_buy, with an average price target of $27.91 (+179% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 31.3%** (YTD 68.7%, 3-mo 15.6%). The shares are up 31.3% over twelve months including dividends.
- **From 52-week high: -12.7%** (122.0% above the low). Trading 13% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 2.04** (volatility 82%). Beta of 2.04 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SGMT · Page: https://foliofundamentals.com/stocks/sgmt

Not investment advice.